1 Potential health and economic impact of paediatric vaccination using next generation

2 influenza vaccines in Kenya: a modelling study

- 3
- 4 **Authors:** Naomi R Waterlow^{1,†}, Sreejith Radhakrishnan¹, Jeanette Dawa^{2,3}, Edwin van
- 5 Leeuwen^{1,4}, Philipp Lambach⁵, Joseph Bresee⁶, Marie Mazur⁷, Rosalind M Eggo¹, Mark Jit¹
- 6
- 7 ¹ Centre for Mathematical Modeling of Infectious Disease, London School of Hygiene and
- 8 Tropical Medicine, London WC14 7HT, United Kingdom
- 9 ² Center for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya
- ³ Washington State University Global Health Kenya, Nairobi, Kenya
- ⁴ Statistics, Modelling and Economics Department, UK Health Security Agency, London NW9
- 12 5EQ, United Kingdom
- ⁵ Immunization Vaccines and Biologicals Department, World Health Organization, Geneva,
- 14 Switzerland
- ⁶The Task Force for Global Health, Decatur, GA, USA
- ⁷Ready2Respond, USA
- 17
- 18 [†] corresponding author. naomi.waterlow1@lshtm.ac.uk

19 Abstract:

- 20 Background: Influenza is a major year-round cause of respiratory illness in Kenya,
- 21 particularly in children under 5. Current influenza vaccines result in short-term, strain-specific
- immunity and were found in a previous study not to be cost-effective in Kenya. However,
- 23 next generation vaccines are in development that may have a greater impact and cost-
- 24 effectiveness profile.

26	Methods: We expanded a model previously used to evaluate cost-effectiveness of seasonal
27	influenza vaccines in Kenya to include next generation vaccines by allowing for enhanced
28	vaccine characteristics and multi-annual immunity. We specifically examined vaccinating
29	children under 5 years of age with improved vaccines, evaluating vaccines with
30	combinations of increased vaccine effectiveness, cross protection between strains (breadth)
31	and duration of immunity. We evaluated cost-effectiveness using incremental cost-
32	effectiveness ratios (ICERs) and incremental net monetary benefits (INMBs) for a range of
33	values for the willingness-to-pay (WTP) per DALY averted. Finally, we estimated threshold
34	per-dose vaccine prices at which vaccination becomes cost-effective.
35	
36	Results: Next generation vaccines can be cost-effective, dependent on the vaccine
37	characteristics and assumed WTP thresholds. Universal vaccines (assumed to provide long-
38	term and broad immunity) are most cost-effective in Kenya across three of four WTP
39	thresholds evaluated, with the lowest median value of ICER per DALY averted (\$263, 95%
40	Credible Interval (CrI): \$-1698, \$1061) and the highest median INMBs. At a WTP of \$623,
41	universal vaccines are cost-effective at or below a median price of \$5.16 per dose (95% Crl:
42	\$0.94, \$18.57). We also show that the assumed mechanism underlying infection-derived
43	immunity strongly impacts vaccine outcomes.
44	
45	Conclusion: This evaluation provides evidence for country-level decision makers about
46	future next generation vaccine introduction, as well as global research funders about the
47	potential market for these vaccines. Next generation vaccines may offer a cost-effective
48	intervention to reduce influenza burden in low-income countries with year-round seasonality
49	like Kenya.

50

51 Keywords: influenza; vaccination; cost-effectiveness; mathematical modelling; next-

52 generation vaccines; health economics

53 Background

54	Influenza is a major cause of respiratory illness in Kenya, particularly in children under 5
55	years old (1,2). Current influenza vaccines result in short-term, strain-specific immunity (3)
56	which is particularly problematic in tropical and subtropical settings where multiple peaks
57	and identifiable year-round activity make it challenging to decide if, who and when to
58	vaccinate, as well as which formulation (northern or southern hemisphere) to use (4-7).
59	Existing vaccines have been evaluated for cost-effectiveness in Kenya, looking at the
60	potential impact of vaccinations in 2010 to 2018 (2). This analysis showed that vaccinating
61	children in Kenya with currently available vaccines was not cost-effective, given current
62	willingness-to-pay thresholds (2). Barriers to cost-effectiveness of influenza vaccination
63	include inconsistent seasonality (with high burden across the year in some years), multiple
64	subtypes of influenza, varying vaccine effectiveness depending on match to circulating
65	influenza strains and the need for annual revaccination(8).
66	

Many of these obstacles could be addressed by next generation vaccines on the near horizon, with 18 vaccines in clinical trials (10 in phase I, 6 in phase II and 2 in phase III trials), and over 100 in preclinical trials (9,10). Newer technologies are being trialled, for example mRNA vaccines and self-assembling nano-particles, and many of these vaccines aim to overcome the immunodominance of the haemagglutinin (HA) head, instead focusing on more conserved proteins across influenza strains and often aiming to stimulate a T-cell response (9).

74

75 The World Health Organisation (WHO) Preferred Product Characteristics (PPC) (11)

76 describes next generation influenza vaccines in two categories: improved vaccines, which

77 have increased vaccine efficacy (VE) or strain cross-protection (breadth) and which generate

- 78 immune protection lasting at least a year; and universal vaccines, which have increased
- 79 efficacy against influenza A phylogenetic HA group viruses and which generate immune

80	protection lasting at least 5 years. These descriptions are based on the likelihood of
81	development in the near to mid future. The US National Institute of Allergy and Infectious
82	Diseases (NIAID) uses similar but slightly varying definitions (12). Such next generation
83	vaccines may hold promising benefits for countries like Kenya, but their potential population
84	impact and cost-effectiveness have yet to be evaluated. Such evaluations could inform
85	country-level decision makers about potential future vaccine introduction, as well as global
86	research funders about the potential market for these vaccines.
87	
88	Mathematical models are ideal tools for evaluating their cost-effectiveness, as they allow
89	analysis and comparison of potential hypothetical interventions and strategies. Specifically,
90	transmission dynamic models have the additional advantage of including both direct and
91	indirect benefits of vaccination. This allows evaluation of optimal control strategies including
92	coverage and timing of vaccination campaigns and vaccine characteristics, such as subtype
92 93	coverage and timing of vaccination campaigns and vaccine characteristics, such as subtype broadness vs efficacy considerations.
92 93 94	coverage and timing of vaccination campaigns and vaccine characteristics, such as subtype broadness vs efficacy considerations.

96 seasonal vaccines in Kenya to evaluate the cost-effectiveness of next generation vaccines.

97

98 Methods

99 Overview

100 We utilise a transmission model from Baguelin et al. (2013) (13) that was fitted to Kenya

101 severe acute respiratory illness (SARI) data from 2010 - 2018 by Dawa et al. (2013) (2) and

102 extend it to include next generation influenza vaccines with longer durations of immunity,

103 higher efficacy and/or broader sub-type cross-protection (Figure 1). Code is available at

104 <u>https://github.com/NaomiWaterlow/NextGenFlu Kenya</u>



- 105
- 106

107 Figure 1 - Modelling overview: A) Methods overview, depicting inputs, models and outputs. 108 B) Model diagram, including both the epidemic and the vaccination model. Elements in solid 109 green are included in both models. Transitions in grey are included only in the epidemic 110 model, and transitions in dotted green are included only in the vaccination model. States are: 111 Susceptible (S), Exposed (E), Infectious (I) and Recovered (R), and their vaccinated 112 counterparts (Sv, Ev1, Ev2, Iv1, Iv2, Rv). v denotes the vaccinated equivalent of the 113 compartments. See Table S3 for parameter details. is the rate of vaccination in age group is the efficacy by subtype (), is vaccine derived immunity waning. The model is run 114 115 separately for each subtype. For the epidemic model, in both vaccinated and unvaccinated 116 compartments, susceptibles who are infected with the viral subtype enter the first Exposed 117 (E) compartment. They then progress through the E and Infectious (I) compartments. After 118 ceasing to be infectious they enter the R compartment, whereupon they cannot be re-119 infected during the same epidemic period. Both the E and I populations consist of two

120 compartments, in order to get a gamma distributed waiting time. Each compartment is also

121 subdivided by age (i).

122 Model 1 - Vaccination model

123 The vaccination model (Figure 1B - green compartments) tracks the dynamics of vaccine-124 induced immunity for each virus subtype without considering prior infection or vaccination 125 status. This is a conservative assumption, assuming vaccination status in the population is 126 unknown and hence people are vaccinated independent of whether they were recently 127 infected or vaccinated. At the time of vaccination the population can be in 1 of 3 128 compartments: Susceptible (S), Susceptible-vaccinated (Sv) and Recovered-vaccinated (Rv) 129 (Figure 1A, green). Vaccination is assumed to be all-or-nothing, with a proportion defined by 130 the efficacy for each subtype entering the Rv compartment where they are immune, and the 131 inverse proportion entering the Sv compartment, where they are susceptible. Waning of 132 vaccination from compartments Sv and Rv occurs exponentially at a rate, ω , determined by 133 the duration of vaccine-induced immunity, returning the population to the Sv compartment. 134 135 We consider scenarios where vaccines have characteristics matching either currently 136 available seasonal influenza vaccines, or next generation vaccines in line with WHO 137 Preferred Product Characteristics (11) (input 1). In the first year, all 0-5 year olds are 138 vaccinated across all vaccine scenarios. Following this, vaccination occurs every x years, 139 calculated as a proportion of the age group, where x is the mean duration of vaccine derived 140 immunity. We generate 5 vaccine scenario examples, corresponding to four categories of 141 Preferred Product Characteristics: current seasonal vaccines, minimally improved vaccines, 142 improved efficacy vaccines, improved breadth vaccines, and universal vaccines (Table 1). 143 We consider vaccines to be either 'matched' or 'mis-matched' to circulating strains each 144 season, and a different efficacy is given in these cases (see supplement for more details). 145

- 146 Table 1: Illustrative vaccine scenarios. "Mis-matched seasons" refers to the possibility that
- 147 the vaccine is not well matched to a particular season's influenza strain and therefore has
- 148 reduced efficacy. Immunity duration is assumed to be exponential. All vaccines are given as
- 149 a campaign, across March, April and May.

Scenario name	Mis-	Efficacy	Immunity Duration	Coverage	Age-groups
	matched	(Matched/Mis-			vaccinated
	seasons?	matched)			
No Vaccine	-	-	-	-	-
Current Seasonal	Yes	70% / 40%	6 months	50%	All 0-5
Vaccines					
Improved vaccines	Yes	70% / 40%	1 year	50%	All 0-5
(Minimal)					
Improved Vaccines	Yes	90% / 70%	2 years	50%	All individuals
(Efficacy)					aged 0-5 in the
					first year of
					vaccination,
					followed by age 0,
					2 and 4 in
					subsequent years
Improved Vaccines	No	70% / 70%	3 years	50%	All individuals
(Breadth)					aged 0-5 in the
					first year of
					vaccination,
					followed by age 0,
					2 and 4 in
					subsequent years
Universal Vaccines	No	90% / 90%	5 years	50%	All individuals
					aged 0-5 in the
					first year of
1					

			vaccination,
			followed by age 0
			and 5
150			

151 We also run sensitivity analyses where vaccination coverage is 75% for all vaccines,

allowing for higher uptake upon new vaccine development (Supplement Section 9).

153

154	We run the model from 1 March 2010, where 1 March each year is considered the start of
155	the southern hemisphere (SH) influenza season. The model runs with given inputs until 31
156	August, as we define 1 September as the start of the Northern Hemisphere (NH) influenza
157	season. VE can differ between seasons to take account of vaccine matched or mis-matched
158	strains. As in Dawa et al. (2020) we identify each season's strain as matched or mis-
159	matched to vaccination based on published VE data (Table S1) and assume that a VE >=
160	50% is a matched vaccine, and < 50% is a mis-matched vaccine. Following the NH season,
161	the population size is updated (see Supplement section 1), and ageing of the population
162	occurs, to allow for a build up of immunity in the relevant age groups. The model runs from 1
163	March 2010 to 28 February 2019. We model transmission of each influenza subtype
164	separately (A(H1N1), A(H3N2), B) to allow different vaccine efficacies across subtypes. We
165	assume all individuals are born susceptible to infection.
166	
167	This vaccination model outputs the proportion of the population that is vaccinated, and of this
168	the proportion that is immunised for each subtype every week over the modelled period.
169	Model 2 - Epidemic Model
170	We model the 11 subtype-specific epidemic time periods that were identified and fitted in
171	Dawa et al. (2020) (Figure 2A). As in Dawa et al. (2020) we define influenza epidemics to

172 start at the first week of a time period consisting of "≥2 successive weeks where the

173 proportion of subtype-specific test-positive cases was greater than the average weekly

174	proportion during the entire study" (Figure 2A). Where an epidemic was previously defined to
175	last less than 8 months, we follow it for the full 8 months to allow capturing the
176	consequences of a slower epidemic progression as the result of vaccination. At the start of
177	each epidemic the proportion of the population in the S , Sv and Rv compartments is taken
178	from the output of the vaccination model, in the matching week and for the relevant virus
179	subtype.Vaccine efficacy is split into NH and SH time frames as in the vaccination model.
180	For each epidemic we run an independent transmission model (with structure of Figure 1B)
181	with the estimated transmission rate, susceptibility for three age groups (<= 14, 15-49, 50+),
182	initial number of infections and the probability of identifying an influenza-positive patient
183	within the catchment population for 3 age groups (<1, 1-5, 6+) from Dawa et al. (2020).
184	Influenza immunity is assumed to be leaky. Supplement section 2 contains the model
185	equations, parameters and values.
186	
187	For key transmission parameters (transmission rate, susceptibility, number of infections at
188	the start of the season, number of imports and ascertainment rates), we use the estimated
189	values by Dawa et al. 2020 for each of the 11 strain/subtype-specific peaks in influenza
190	activity identified between 2010 - 2018 (input 2). The parameter values for each
191	strain/subtype-specific peak are estimated independently, using the fluEvidenceSynthesis R

package. We also use the same age groups (<1, 1–5, 6–14, 15–19, 20–49 and≥50 years

193 old) contact patterns and population sizes. For more details see Dawa et al. (2020).

194

195 In our main analysis we assume that the previous season's vaccination has no effect on the

196 proportion of people who have infection-derived immunity at the start of the next season.

197 This is supported by statistical analyses indicating that susceptibility at the start of each

198	season (based on the model fit in Dawa et al. (2020)) is not strongly dependent on infections
199	in the previous season (Supplement section 4). To explore the possibility that there is some
200	dependency, we run sensitivity analyses with two different assumptions on changes in
201	susceptibility (Supplement section 9).

- 202 Model 3 Background FOI
- 203 To characterise influenza epidemiology in Kenya, we use weekly numbers of hospitalised

204 patients with SARI from 2010-2018 from the Kenyan National SARI surveillance system

- 205 (input 3). Data from a subset of 5 large hospitals that have a bed capacity of over 200 and a
- 206 well-established surveillance system in place is used. The case definition of SARI was a
- 207 hospitalised patient with acute illness onset presenting with fever or cough. A random
- sample of these patients underwent virological analysis to identify the presence or absence
- 209 of influenza. For further details and data access, see Dawa *et al.* (2020).
- 210
- 211 To account for infections in the inter-epidemic periods, we include a background rate of
- 212 infection with a Poisson distribution with shape parameter $\Lambda_{i,k}$, fitted to the weekly observed

213 cases in each age group and of each subtype across all inter-epidemic periods. We then

calculate the weekly number of background infections per age group, i, and subtype, k,

215 across the whole time period:

216

Background Infections_{t,i,k} =
$$\sum_{i=1}^{n=6} \Lambda_{i,k} * (sus_{t,i,k}/asc_{i,k})$$

217

218 Where $sus_{t,i,k}$ is the proportion susceptible each week (*t*) for age group *i* and influenza 219 subtype *s* outputted from the vaccination model, $asc_{i,k}$ is the mean ascertainment rate by 220 age group as estimated in the Dawa *et al.* (2020) paper.

221 Model 4 - Economic analyses

222	We estimate the incremental cost-effectiveness of each of the vaccine scenarios in Table 1
223	(compared to no vaccination), following WHO recommendations for economic evaluations of
224	vaccines (14). The analytic time horizon used in the economic analyses is the same as the
225	epidemiological model (2010-2019 inclusive), except that life years lost due to death are
226	counted until the full normal life expectancy. Information on input costs used in these
227	analyses (input 4) can be found in the Supplement section 8. We adopt a societal
228	perspective on costs, and both costs and health outcomes are discounted at 3% per annum,
229	with 0% discounting for health outcomes in a sensitivity analysis. All costs (except vaccine
230	costs) are expressed in terms of 2019 USD and costs from other years are adjusted using
231	Kenya gross domestic product (GDP) deflator values (15) before calculating cost-
232	effectiveness measures.
233	
234	Uncertainty is captured using probabilistic sensitivity analysis. This is done by drawing 1000
235	random samples per vaccine scenario of the total number of influenza infections generated
236	from 2010 to 2019 by all virus subtypes across all age groups and charting disease and
237	hospitalisation outcomes for each infection. Adopting the same approach as Dawa et al.
238	(2020), we use a decision tree (Supplement section 8) to project health-related outcomes
239	associated with influenza infections. Samples of probability parameters are drawn from a
240	beta distribution (16) whose shape parameters were calculated first by fitting the mean and
241	95% confidence intervals for each probability parameter (drawn from the literature) to a beta

242 distribution (2).

243

We further divide symptomatic infections into mild (upper respiratory tract infections, URTI) or severe (lower respiratory tract infections, LRTI) illness. Patients with mild illness will receive medical attention at outpatient clinics and eventually recover. Severely ill patients go

on to be hospitalised, and further progress to recover from illness or die. The mean durations
of influenza-associated illness and length of hospital stay are assumed to be 4 days (17,18).

249

250 A range of influenza-related healthcare utilisation events such as seeking medical care at 251 outpatient clinics, hospitalisation as inpatients and purchase of over-the-counter medication 252 are assumed to incur healthcare costs. To capture uncertainty around these costs, random 253 samples of cost parameters are drawn from a gamma distribution (16). Direct medical costs 254 include the price of influenza vaccines, assumed to be \$3 per dose, and vaccine wastage, 255 assumed to be 15% (2). Healthcare related costs include transportation costs for hospital 256 visits to seek medical care for influenza-associated illness or for influenza vaccination. 257 Similarly, indirect costs include lost wages and childcare costs due to influenza-related 258 illness (see supplement section 8, and Figure 1 and Tables 2 and 3 in Dawa et al., (2020) for 259 parameter values and references).

260

For health outcomes, we calculate disability-adjusted life years (DALYs) using disability weights for mild URTI, moderate and severe LRTI and death (GBD, 2019). In contrast to Dawa et al. (2020), no age-weighting of DALYs is done, as this is no longer recommended (14).

265

266 We determine cost-effectiveness of vaccination scenarios by calculating median incremental 267 cost-effectiveness ratios (ICERs) per DALY averted and median incremental net monetary 268 benefits (INMBs) across all ten years for each vaccine scenario compared to the no 269 vaccination scenario. The most cost-effective scenario is the one with the lowest ICER value 270 and the highest INMB value. In the absence of locally-determined cost-effectiveness 271 thresholds for health interventions in Kenya, ICERs are evaluated against a WHO 'best buy' 272 threshold of \$100 per DALY averted in LMICs as well as cost-effectiveness thresholds 273 derived using two broad approaches - marginal productivity thresholds calculated by the 274 University of York (19) and those based on global analyses by the Commission for

Macroeconomics and Health (20). While results using four WTP thresholds (Table 2) are presented in the main paper, details of the full range of thresholds used and corresponding results are presented in the supplement (section 8). These thresholds are also used to calculate vaccine prices at or below which a vaccination scenario is deemed cost-effective.

All results presented in the main text are calculated using discounted costs and DALYs. In sensitivity analyses, undiscounted costs are also used. We also analyse the effect of changing the vaccine price to \$1.50, \$6 and \$10 per dose.

283

WTP threshold (USD)	Description*	Reference
100	WHO best buy	(21)
623	45% Kenya pc GDP (2015)	(19)
1912.65	1x Kenya pc GDP (2019)	(22)
5737.95	3x Kenya pc GDP (2019)	(22)

284 Table 2: Selected willingness to pay (WTP) thresholds used in this study

285 *pc GDP - per capita gross domestic product

286 Results

287 Cases averted and doses used

288

289 While all modelled vaccine types increased the proportion of the population with some

290 immunity, Universal vaccines resulted in the highest levels of immunity across the whole

291 period (Supplemental section 7). In addition, this resulting immunity was generated with

292 fewer vaccine doses due to slower waning, with a total of 14 million vaccine doses used for

293 the Universal vaccine scenario over the whole time period. The same number of vaccines

- 294 were used for Improved vaccine (breadth) scenarios, 19 million for Improved vaccine
- 295 (efficacy) scenarios and 30 million for the Current seasonal vaccines and the Improved
- 296 vaccines (Minimal) scenario.
- 297



298



303

304 The high immunity from Universal vaccines translated into the biggest projected reduction in

305 cumulative infections across the 10 year period with a median total of 66% of infections

averted (95% Credible Interval (CrI) 56%-74%) as compared to the no vaccination scenario.

- 307 This compared to the Improved (Efficacy) of 57% (95% Crl 47 67%), Improved (Breadth) of
- 308 51% (95% Crl 42%- 61%), Improved (Minimal) 41% (95% Crl 33% 49%) and Current
- 309 seasonal of 29% (95% Crl 23% 35%) infections averted. The mean R_0 of influenza across

310	epidemics was 2.2 (range 1.2 - 6.7, Supplement section 8 for further details) and across
311	vaccination scenarios the average number of cases averted per vaccine dose ranged from

312 0.33 to 2.6.

313

314 <u>Cost-effectiveness</u>

315

316 Programmes using Universal and Improved (Breadth) vaccines incurred the lowest total 317 vaccine purchase and administration costs across the entire period, assuming per-dose 318 vaccine costs are the same for all vaccines (\$3), because they required the fewest doses. 319 These amounted to a median total value of \$78.86 million (95% Crl: \$60.96, \$125.18 (in 320 millions)), compared to \$108.54 million for Improved (Efficacy) and \$167.91 million for both 321 Improved (Minimal) and Current seasonal (Supplement section 8). After accounting for these 322 costs and the costs of travel to seek vaccination, programmes using universal vaccines 323 incurred the lowest total societal costs (direct medical, healthcare-related and indirect costs) 324 and thereby incremental total costs, compared to when no vaccination was conducted 325 (Figure 3A). Median discounted incremental total costs for Universal vaccines were \$27.67 326 million (95% Crl: \$-174.38, \$78.21 (in millions)). In contrast, median discounted incremental 327 costs were higher for all Improved vaccines and highest for Current seasonal vaccines 328 (\$128.64 million (95% Crl \$35.62, \$228.43 (in millions)) (Supplement section 8).







- averted when evaluating cost-effectiveness using discounted costs and DALYs (Figure 3).
- 339 While there was overlap between uncertainty ranges of ICER values calculated for all five

340	vaccines, Universal vaccines were cost-effective across three of the four WTP thresholds
341	evaluated in this study, with a median ICER per DALY averted of \$263 (95% CrI: \$-1698,
342	\$1061) (Figure 3B). Similarly, Improved (breadth) vaccines were cost-effective across three
343	of four WTP thresholds with a median ICER value of \$422 per DALY averted, while
344	Improved (Efficacy) vaccines had a median ICER value of \$626, being cost-effective across
345	two of four thresholds. In contrast, Current seasonal vaccines had a median ICER value of
346	\$2764 per DALY averted, being cost-effective only at a WTP threshold of 3 times the 2019
347	per capita GDP of Kenya of approximately \$5738 (Figure 3B, Supplement section 8). Thus,
348	median ICER values for Improved (Breadth), Improved (Efficacy) and Current seasonal
349	vaccines were 1.60, 2.38 and 10.51 times higher than for Universal vaccines, respectively.
350	
351	Similarly, Universal vaccines had the highest median INMB values across all WTP
352	thresholds (Figure 3C). At a threshold of \$623 (45% of Kenya's 2019 per capita GDP), the
353	median INMB value of Universal vaccines (\$39.6 million) was 2.29 times higher than that of
354	Improved (Breadth) (\$17.26 million) vaccines (Supplement section 8). At this threshold,
355	Universal vaccines had a high probability (>75%) of being cost-effective, at or below a
356	median price of \$5.16 per vaccine dose (95% Crl: \$0.94, \$18.57) (Table 3, Fig. S7,
357	supplement section 8). Calculated threshold per-dose vaccine prices were consistently
358	higher for Universal vaccines across all WTP thresholds. Universal vaccines had median
359	INMB values 4.21 times higher than that of Current seasonal vaccines (\$134.63 million) at a
360	WTP threshold of \$5738.
361	

Table 3: Median (and 95% Crl) values of threshold per-dose vaccine prices (2019 USD) at or
below which each vaccination scenario is cost-effective, calculated using discounted costs
and DALYs, at four selected thresholds of willingness-to-pay per DALY averted. These are
calculated while including a median vaccine administration cost of \$1.31 per dose (gamma
distributed).

Vaccine	WHO best	45% per capita	1x per capita	3x per capita
	buy (\$100)	GDP (\$623)	GDP (\$1913)	GDP (\$5738)
Current	-0.87 (-3.74,	-0.14 (-2.92,	1.54 (-1.43,	6.51 (1.54,
seasonal	1.85)	2.63)	5.79)	16.66)
Improved	-0.58 (-3.48,	0.45 (-2.49,	2.86 (-0.69,	9.97 (3.52, 23.2)
(minimal)	3.29)	4.38)	8.77)	
Improved	0.98 (-2.05,	3.77 (0.03,	10.4 (4.05, 25.4)	29.47 (13.83,
(breadth)	10.85)	14.02)		64.04)
Improved	0.46 (-2.42,	2.67 (-0.71,	7.99 (2.69,	23.31 (10.78,
(efficacy)	8.38)	10.9)	19.89)	50.57)
Universal	1.59 (-1.51,	5.16 (0.94,	13.67 (5.99,	37.8 (18.74,
	14.2)	18.57)	31.68)	79.06)

367

*pc GDP - per capita gross domestic product

368

369 In our sensitivity analyses, increased coverage of vaccination made only slight differences to 370 the cost-effectiveness of any of the vaccines across the different WTP thresholds evaluated 371 (supplement, section 9). The number of cases averted per vaccine dose was slightly lower 372 than in the 50% coverage scenario, ranging from 0.31 - 2.16. In addition, we found that 373 assumptions around susceptibility had a large impact on impact and cost-effectiveness. If we 374 assumed that greater reduction in infections in one season increased susceptibility in the 375 next season, then vaccines were less impactful and cost-effective (see supplement section 376 10 for details).

378 Discussion

379 Our study indicates that next generation vaccines are likely to have much greater impact and 380 an improved cost-effectiveness profile than currently available influenza vaccines. This is 381 true even for incrementally improved vaccines with slightly greater breadth or duration. 382 These are evidenced by the scale of reduction in influenza infections and improvements in 383 cost-effectiveness measures, particularly for universal vaccines. Universal vaccines result in 384 the most substantial reduction in influenza infections utilising the least vaccine doses, 385 averting 66% of infections compared to no vaccination. In contrast, our model predicts that 386 current vaccines avert only 29% of infections, while even improved (minimal) vaccines avert 387 41% of infections. Similarly, ICER values are higher for improved (1.60 to 2.38 times) and 388 current seasonal (10.51 times) vaccines than for universal vaccines. Universal vaccines also 389 have the highest INMB values - 2.29 times higher than Improved (breadth) vaccines at a 390 WTP threshold of \$623, and 4.21 times higher than current seasonal vaccines at a WTP 391 threshold of \$5738, the only threshold at which current vaccines are cost-effective. Thus our 392 results suggest that universal vaccines result in the highest immunity per vaccine dose and 393 subsequently, the least number of infections, as well as having the most favourable cost-394 effectiveness profile among all the vaccines evaluated.

395

396 Our conclusions are influenced by vaccine dose costs and cost-effectiveness thresholds. We 397 assumed that vaccine per-dose costs are the same for all vaccines (\$3), which is unlikely to 398 be true. More advanced vaccines may cost more per dose. As a comparison, SARS-Cov-2 399 AstraZeneca vaccines, which were sold without profit, cost between \$2.15 and \$5.25 per 400 dose, compared to mRNA SARS-CoV-2 vaccines costing \$14.70 to \$23.50 per dose (23). 401 Nevertheless, our estimates of the threshold per-dose vaccine price (prices at or below 402 which vaccination programs are cost-effective) suggest that universal vaccines are cost-403 effective even when priced higher than current seasonal or improved vaccines and 404 irrespective of the WTP threshold. At the same time, we find that improved vaccines can

405 also be cost-effective at comparatively low WTP thresholds and result in fewer influenza 406 cases than currently available seasonal vaccines, even if priced higher per dose. The 407 development and use of universal vaccines are very likely to benefit low-and-middle-income 408 countries which may only be willing or able to pay less for health benefits than more 409 advanced economies. However, universal vaccines are unlikely to be immediately available 410 for widespread use, but improved vaccines offer substantial value as an achievable and 411 satisfactory alternative to current influenza vaccines, especially since these may be available 412 in the near future.

413

414 Our analyses demonstrate the importance of assumed cost-effectiveness thresholds when 415 determining whether health interventions are cost-effective or not. Kenya does not have an 416 official cost-effectiveness threshold, but Dawa et al. (2020) reported that vaccination with 417 current seasonal influenza vaccines in Kenya had a low probability of being cost-effective 418 given WTP thresholds of 1-51% of per capita GDP. To address uncertainty around 419 thresholds, we used a wide range of values ranging from extremely low WHO "best buys" 420 threshold reserved for evaluating some of the most cost-effective programmes that WHO 421 has ever evaluated (21), to very high 1-3 times GDP per capita thresholds representing the 422 potential value of human capital associated with disability (24). Like Dawa et al., we find that 423 current vaccines are cost-effective only at a very high threshold of 3 times the per capita 424 GDP of Kenya and at a maximum threshold price of \$6.51 per dose, which is much lower 425 than prices at which most influenza vaccines are available in the US (25) or UK (26). 426 Conversely, both universal and improved influenza vaccines are cost-effective at lower 427 thresholds. 428

429 A key strength of our epidemiological model is the direct incorporation of vaccine-derived 430 immunity waning over multiple years, with ageing of the population, which is required to 431 evaluate next generation vaccines with benefits that last several years. This contrasts to 432 many seasonal vaccination models where vaccine-derived immunity is not tracked across

433 seasons (2,13). In contrast with the marked annual seasonality of influenza in temperate 434 regions (27), influenza epidemics in Kenya do not have a regular seasonal pattern, with 435 substantial transmission in between epidemics, which we included by separately modelling 436 the inter-epidemic periods. However we used a relatively simple approach for this and we do 437 not capture indirect effects of vaccination between epidemics. In addition, while we include 3 438 influenza subtypes (AH1N1, A H3N2 and B), we do not allow for any interaction between 439 these subtypes, which may contribute to the dynamics of transmission (28–33). However, as 440 our modelling is based on fitted models, this should not have major impacts on our economic 441 analysis. Therefore the main practical disadvantage is that we are unable to investigate 442 vaccines with different efficacies within the influenza B viruses. 443 444 Country decisions to invest in health interventions can be influenced by considerations other 445 than cost-effectiveness (34), for example due to competing options for implementation or 446 due to widespread vaccine hesitancy. Whilst our modelling indicates that next generation 447 vaccines can be cost-effective, their implementation will be competing against other public

448 health interventions. In Kenya, separate studies have shown both rotavirus and

449 pneumococcal childhood vaccination to be cost effective, with between \$25 and \$59 (35)

450 and \$38 (36) per DALY averted respectively, and programmes covering these vaccines have

451 been introduced. However, these estimates are substantially lower than for even the

452 universal influenza vaccines calculated here. Equity in vaccine distribution (37) is also a key

453 consideration for vaccine programme implementation. The availability of financing options
454 such as from Gavi, the Vaccine Alliance (38), is also important, but Kenya is already starting
455 to transition out of Gavi support.

456

457 Our study has a number of other limitations. We have assumed that vaccination occurs458 independent of current vaccine status, meaning that individuals can receive multiple

459 vaccinations and therefore some vaccinations will be 'wasted' on individuals already

460 immune. This is a conservative assumption, likely making the vaccine scenarios appear less

461 cost-effective, and is more likely to have an effect at higher coverage levels. It is also 462 recommended that children between 6 months and 8 years of age, or those who have only 463 ever received one dose, should receive two vaccine doses at least 4 weeks apart (39,40). 464 Administration of a second vaccine dose will incur additional costs for vaccine purchase, 465 transport and administration, although these additional costs may be off-set by vaccinating 466 independent of vaccine status. In reality, there may also be challenges to administer 467 vaccines twice due to limited access. We also do not consider adverse vaccine reactions 468 (40,41) in our DALY calculations. These would influence cost-effectiveness and vaccine 469 threshold prices, particularly at lower cost-effectiveness thresholds.

470

471 Immune protection to influenza virus infection and vaccination are poorly understood and we 472 found that assumptions on infection-derived immunity have a large impact on incidence and 473 resulting cost-effectiveness estimates. However, such assumptions could not be empirically 474 informed, because in this setting the previous season does not have an impact on estimated 475 susceptibility levels in the following season and our sensitivity analyses with different 476 infection-susceptibility assumptions show different behaviour than observed for current 477 seasonal vaccines. Therefore our main analysis presents the most likely assumptions. 478 Another important consideration is the potential population-level effects of universal vaccines 479 on vulnerability to newer influenza virus variants. Previous mathematical modelling studies 480 suggest that universal vaccines can prevent the development of cross-protective immunity 481 developed through natural infection. In the absence of sufficiently high vaccination coverage, 482 it was thus suggested that universal vaccines can increase the risks of emergence of 483 vaccine escape variants that could cause influenza pandemics (42,43). These studies 484 suggest that combining administration of seasonal and universal vaccines may help to 485 mitigate these risks (42), a strategy which we have not explored in our study.

486 Conclusions

487

- 488 Our study provides the first formal evaluation incorporating both direct and indirect (herd)
- 489 protection, of the effectiveness and cost-effectiveness of a range of next generation
- 490 influenza vaccines meeting WHO PPCs. In doing so it bolsters the case for investing in
- 491 development of these vaccines, while highlighting the benefits to be derived from improved
- 492 vaccines. This provides proof-of-principle for similar studies to be conducted in other LMICs,
- 493 so that a global picture of potential demand for these vaccines can be built.

494 List of Abbreviations

- 496 Crl Credible Interval
- 497 DALY disability-adjusted life years
- 498 E Exposed
- 499 GDP gross domestic product
- 500 HA haemagglutinin
- 501 I infectious
- 502 ICER incremental cost-effectiveness ratio
- 503 INMB incremental net monetary benefits
- 504 LMIC lower middle-income countries
- 505 LRTI lower respiratory tract infections
- 506 NH Northern Hemisphere
- 507 NIAID National Institute of Allergy and Infectious Diseases
- 508 PPC Preferred product characteristics
- 509 R recovered

- 510 Rv Recovered-vaccinated
- 511 S Susceptible
- 512 SARI severe acute respiratory illness
- 513 SH Southern Hemisphere
- 514 Sv Susceptible-vaccinated
- 515 URTI upper respiratory tract infections
- 516 USD US Dollars
- 517 VE Vaccine efficacy
- 518 WHO World Health Organisation
- 519 WTP Willingness-to-pay
- 520 Declarations
- 521 Ethics Approval
- 522 Not applicable.
- 523 Consent for publication
- 524 Not applicable
- 525 Availability of data and materials
- 526 The datasets analysed during the current study are available in the Supplement of Dawa et
- 527 al. (2020). (https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-020-01687-
- 528 <u>7#Sec18</u>)
- 529 All code is available at <u>https://github.com/NaomiWaterlow/NextGenFlu Kenya</u>.
- 530
- 531 Competing Interests
- 532 The authors declare that they have no competing interests.
- 533
- 534 Funding

535	This work was funded by the Wellcome Trust, Centers for Disease Control and
536	Prevention and Taskforce for Global Health via the grant "Modeling cost-
537	effectiveness of improved seasonal influenza vaccines in two exemplar countries".
538	JB was funded by PIVI and CDC. EvL and RME were also supported by the National
539	Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in
540	Modelling and Health Economics, a partnership between UK HSA, Imperial College
541	London, and LSHTM (grant number NIHR200908) and EvL was also supported by
542	the European Union's Horizon 2020 research and innovation programme - project
543	EpiPose (101003688).
544	
545	Authors contributions
546	RME, MJ, JB and MM contributed to the conception of the project. RME, MJ, JD,
547	NRW, SR and EvL contributed to the design of the work. NRW, SR, JD and EvL
548	contributed to the analysis of the work. NRW, SR, JD, EvL, JB, MM, PL, RME and
549	MJ contributed to the interpretation of the data. NRW, SR and JD contributed to the
550	creation of the new software in the work. NRW and SR drafted the manuscript and
551	NRW, SR, JD, EvL, JB, MM, PL, RME and MJ reviewed and edited the manuscript.
552	
553	Acknowledgments

- 554 We would like to acknowledge the advice received from Sandra Chaves, Marc-Alain
- 555 Widdowson and Gideon Emukule.

556 References

557

McMorrow ML, Emukule GO, Njuguna HN, Bigogo G, Montgomery JM, Nyawanda B, et
 al. The Unrecognized Burden of Influenza in Young Kenyan Children, 2008-2012. PLoS

560 ONE. 2015 Sep 17;10(9):e0138272. 561 2. Dawa J, Emukule GO, Barasa E, Widdowson MA, Anzala O, van Leeuwen E, et al. 562 Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic 563 transmission modelling. BMC Med. 2020 Aug 20;18:223. 564 3. Gomez Lorenzo MM, Fenton MJ. Immunobiology of Influenza Vaccines. Chest. 2013 565 Feb;143(2):502–10. 566 4. Hirve S. Seasonal Influenza Vaccine Use in Low and Middle Income Countries in the 567 Tropics and Subtropics [Internet]. World Health Organization; 2015 [cited 2022 Jul 27] p. 99. Available from: https://www.who.int/publications-detail-redirect/9789241565097 568 569 5. Lambach P, Alvarez AMR, Hirve S, Ortiz JR, Hombach J, Verweij M, et al. 570 Considerations of strategies to provide influenza vaccine year round. Vaccine. 2015 Nov 571 25:33(47):6493-8. 572 6. Hirve S, Lambach P, Paget J, Vandemaele K, Fitzner J, Zhang W. Seasonal influenza 573 vaccine policy, use and effectiveness in the tropics and subtropics - a systematic 574 literature review. Influenza Other Respir Viruses. 2016 Jul;10(4):254-67. 575 Vaccine in tropics and subtropics [Internet]. [cited 2022 Aug 17]. Available from: 7. 576 https://www.who.int/teams/global-influenza-programme/vaccines/vaccine-in-tropics-and-577 subtropics 578 8. Matheka DM, Mokaya J, Maritim M. Overview of influenza virus infections in Kenya: 579 past, present and future. Pan Afr Med J. 2013 Apr 8;14:138. 580 9. Universal Influenza Vaccine Technology Landscape | CIDRAP [Internet]. [cited 2022 Apr 581 5]. Available from: https://ivr.cidrap.umn.edu/universal-influenza-vaccine-technology-582 landscape 583 10. Moore KA, Ostrowsky JT, Kraigsley AM, Mehr AJ, Bresee JS, Friede MH, et al. A 584 Research and Development (R&D) roadmap for influenza vaccines: Looking toward the 585 future. Vaccine. 2021 Oct 29;39(45):6573-84. 586 WHO Preferred Product Characteristics for Next-Generation Influenza Vaccines 587 [Internet]. [cited 2022 Jan 6]. Available from: https://www.who.int/publications-detail-588 redirect/9789241512466 589 12. Erbelding EJ, Post DJ, Stemmy EJ, Roberts PC, Augustine AD, Ferguson S, et al. A 590 Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and 591 Infectious Diseases. J Infect Dis. 2018 Jul 2;218(3):347–54. 592 13. Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ. Assessing 593 Optimal Target Populations for Influenza Vaccination Programmes: An Evidence 594 Synthesis and Modelling Study. PLoS Med [Internet]. 2013;10(10). Available from: 595 http://researchonline.lshtm.ac.uk/1273063/ 596 14. WHO. WHO guide for standardization of economic evaluations of immunization 597 programmes [Internet]. 2nd ed. Geneva PP - Geneva: World Health Organization; 2019 598 p. 137–137. Available from: https://apps.who.int/iris/handle/10665/329389 599 15. Inflation, GDP deflator (annual %) - Kenya | Data [Internet]. Available from: 600 https://data.worldbank.org/indicator/NY.GDP.DEFL.KD.ZG?locations=KE 601 16. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. 602 Oxford: Oxford University Press; 2006. 237 p. (Oxford handbooks in health economic 603 evaluation). 604 17. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, et al. Time Lines 605 of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies. 606 Am J Epidemiol. 2008 Apr 1;167(7):775-85. 607 18. Emukule GO, Ndegwa LK, Washington ML, Paget JW, Duque J, Chaves SS, et al. The 608 cost of influenza-associated hospitalizations and outpatient visits in Kenya. BMC Public 609 Health. 2019 May:19(3):1–10. 610 19. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and 611 middle-income countries: a novel approach and evidence from cross-country data. BMJ 612 Glob Health. 2018 Nov;3(6):e000964. 613 20. Loganathan T, Ng CW, Lee WS, Hutubessy RCW, Verguet S, Jit M. Thresholds for 614 decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines

- in Malaysia. Health Policy Plan. 2018 Mar 1;33(2):204–14.
- 616 21. Organization WH. Tackling NCDs: 'best buys' and other recommended interventions for
 617 the prevention and control of noncommunicable diseases [Internet]. Geneva PP 618 Geneva: World Health Organization; 2017 p. 25–25. Available from:
 619 https://apps.who.int/iris/handle/10665/259232
- 620 22. GDP per capita (current US\$) Kenya | Data [Internet]. [cited 2022 Jun 13]. Available
 621 from:
- https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?end=2020&locations=KE&start=
 2018
- 624 23. Light DW, Lexchin J. The costs of coronavirus vaccines and their pricing. J R Soc Med.
 625 2021 Nov 1;114(11):502–4.
- 4. Tan-Torres Edejer T, Baltussen RMPM, Adam T, Acharya A, Evans DB, Murray CJL.
 Making choices in health : WHO guide to cost-effectiveness analysis [Internet]. World
 Health Organization; 2003 [cited 2022 Jul 27]. Available from: https://apps.who.int/iris/handle/10665/42699
- 630
 631
 632
 633
 634
 635
 635
 636
 637
 637
 638
 639
 639
 630
 630
 631
 632
 632
 633
 634
 635
 635
 636
 637
 638
 639
 639
 630
 630
 630
 631
 632
 632
 633
 634
 635
 635
 636
 637
 638
 638
 639
 639
 630
 630
 631
 632
 632
 632
 632
 632
 632
 633
 634
 635
 635
 636
 637
 638
 638
 639
 639
 630
 631
 632
 632
 632
 632
 632
 633
 634
 635
 635
 636
 637
 638
 638
 639
 639
 630
 631
 632
 632
 632
 632
 633
 634
 634
 635
 635
 636
 637
 638
 638
 639
 639
 631
 632
 632
 632
 632
 634
 635
 635
 636
 637
 638
 638
 639
 639
 639
 639
 639
 630
 631
 632
 632
 632
 632
 634
- 633 26. Medicinal forms | Influenza vaccine | Drugs | BNF content published by NICE [Internet].
 634 [cited 2022 Jul 7]. Available from: https://bnf.nice.org.uk/drugs/influenza635 vaccine/medicinal-forms/
- 636 27. Lofgren E, Fefferman NH, Naumov YN, Gorski J, Naumova EN. MINIREVIEW Influenza
 637 Seasonality: Underlying Causes and Modeling Theories. J Virol. 2007;81(11):5429–36.
- Andreasen V, Lin J, Levin SA. The dynamics of cocirculating influenza strains conferring
 partial cross-immunity. J Math Biol. 1997 Aug;35(7):825–42.
- Sonoguchi T, Naito H, Hara M, Takeuchi Y, Fukumi H. Cross-Subtype Protection in
 Humans During Sequential, Overlapping, and/or Concurrent Epidemics Caused by
 H3N2 and H1N1 Influenza Viruses. J Infect Dis. 1985 Jan;151(1):81–8.
- 643 30. Koutsakos M, Illing PT, Nguyen THO, Mifsud NA, Crawford JC, Rizzetto S, et al. Human
 644 CD8+ T cell cross-reactivity across influenza A, B and C viruses. Nat Immunol. 2019
 645 May;20(5):613–25.
- 31. Yang W, Lau EHY, Cowling BJ. Dynamic interactions of influenza viruses in Hong Kong during 1998-2018. Viboud C, editor. PLOS Comput Biol. 2020 Jun;16(6):e1007989– e1007989.
- S2. Lin J, Andreasen V, Levin SA. Dynamics of influenza A drift: the linear three-strain
 model. Math Biosci. 1999 Nov;162(1–2):33–51.
- 33. Waterlow NR, Flasche S, Minter A, Eggo RM. Competition between RSV and influenza:
 limits of modelling inference from surveillance data. Epidemics. 2021 Mar 26;100460.
- 34. Jit M. Informing Global Cost-Effectiveness Thresholds Using Country Investment
 Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018. Value Health.
 2021 Jan 1;24(1):61–6.
- 35. Sigei C, Odaga J, Mvundura M, Madrid Y, Clark AD. Cost-effectiveness of rotavirus
 vaccination in Kenya and Uganda. Vaccine. 2015 May 7;33:A109–18.
- 36. Ayieko P, Griffiths UK, Ndiritu M, Moisi J, Mugoya IK, Kamau T, et al. Assessment of
 Health Benefits and Cost-Effectiveness of 10-Valent and 13-Valent Pneumococcal
 Conjugate Vaccination in Kenyan Children. PLoS ONE. 2013 Jun 24;8(6):e67324.
- 37. Vaccine equity [Internet]. [cited 2022 Jul 8]. Available from:
 https://www.who.int/campaigns/vaccine-equity
- 38. Gavi, the Vaccine Alliance [Internet]. [cited 2022 Jul 8]. Available from:
 https://www.gavi.org/
- 39. CDC. Children & Influenza (Flu) [Internet]. Centers for Disease Control and Prevention.
 2021 [cited 2022 Jul 7]. Available from: https://www.cdc.gov/flu/highrisk/children.htm
- 40. Influenza vaccine | Drugs | BNF content published by NICE [Internet]. [cited 2022 Jul 7].
 Available from: https://bnf.nice.org.uk/drugs/influenza-vaccine/
- 41. Seasonal Influenza Vaccine Safety: A Summary for Clinicians | CDC [Internet]. 2021

- 670 [cited 2022 Jul 7]. Available from:
- 671 https://www.cdc.gov/flu/professionals/vaccination/vaccine_safety.htm
- 672 42. Arinaminpathy N, Riley S, Barclay WS, Saad-Roy C, Grenfell B. Population implications 673 of the deployment of novel universal vaccines against epidemic and pandemic influenza.
- 674 J R Soc Interface. 2020 Mar;17(164):20190879.
- 675 43. Subramanian R, Graham AL, Grenfell BT, Arinaminpathy N. Universal or Specific? A Modeling-Based Comparison of Broad-Spectrum Influenza Vaccines against 676
- 677 Conventional, Strain-Matched Vaccines. Regoes RR, editor. PLOS Comput Biol. 2016 678 Dec 15;12(12):e1005204.